Opendata, web and dolomites

ITCC-P4 SIGNED

ITCC Pediatric Preclinical POC Platform – Sofia ref.: 116064

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ITCC-P4 project word cloud

Explore the words cloud of the ITCC-P4 project. It provides you a very rough idea of what is the project "ITCC-P4" about.

malignant    match    histopathology    therapeutic    unmet    models    facts    accurate    consisting    commercial    precise    line    date    academic    patient    centralized    usually    upfront    matching    biomarkers    private    question    full    drugs    successes    adult    therapy    easier    regarding    appropriate    compounds    options    repertoire    cancer    public    itcc    resistance    malignancies    genetic    disease    qualifications    countries    preclinical    believe    25    death    partnership    mouse    predictive    entities    ideally    first    evolution    counterparts    relapses    scarce    regulatory    efficacious    relapsed    intensive    data    tumor    assured    p4    pediatric    participating    powerful    solid    limited    positioned    genetically    formed    patients    basis    drug    clinical    pharma    molecularly    vivo    anticipated    hampered    quality    spectrum    companies    pharmacology    curative    expertise    medical    children    tumors    bioinformatics    saturated    risk    treatment    molecular    expedite   

Project "ITCC-P4" data sheet

The following table provides information about the project.

Coordinator
DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG 

Organization address
address: IM NEUENHEIMER FELD 280
city: HEIDELBERG
postcode: 69120
website: www.dkfz.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Project website https://www.itccp4.eu/
 Total cost 16˙562˙831 €
 EC max contribution 7˙370˙000 € (44%)
 Programme 1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
 Code Call H2020-JTI-IMI2-2015-07-two-stage
 Funding Scheme IMI2-RIA
 Starting year 2017
 Duration (year-month-day) from 2017-01-01   to  2021-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG DE (HEIDELBERG) coordinator 2˙995˙864.00
2    PRINSES MAXIMA CENTRUM VOOR KINDERONCOLOGIE BV NL (UTRECHT) participant 788˙000.00
3    THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL UK (LONDON) participant 566˙750.00
4    EXPERIMENTELLE PHARMAKOLOGIE UND ONKOLOGIE BERLIN-BUCH GMBH DE (BERLIN) participant 563˙425.00
5    XENTECH SAS FR (Evry) participant 563˙425.00
6    ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM NL (AMSTERDAM) participant 380˙300.00
7    CHARITE - UNIVERSITAETSMEDIZIN BERLIN DE (BERLIN) participant 352˙562.00
8    INSTITUT GUSTAVE ROUSSY FR (VILLEJUIF) participant 280˙912.00
9    INSTITUT CURIE FR (PARIS) participant 214˙038.00
10    ST. ANNA KINDERKREBSFORSCHUNG AT (WIEN) participant 163˙285.00
11    ALLEANZA CONTRO IL CANCRO IT (ROMA) participant 133˙776.00
12    MEDIZINISCHE UNIVERSITAET WIEN AT (WIEN) participant 131˙075.00
13    FUNDACIO SANT JOAN DE DEU ES (Esplugues de Llobregat) participant 129˙050.00
14    INNOVATIVE THERAPIES FOR CHILDREN WITH CANCER ASSOCIATION FR (VILLEJUIF) participant 107˙538.00
15    BAYER AKTIENGESELLSCHAFT DE (Leverkusen) participant 0.00
16    CHARLES RIVER DISCOVERY RESEARCH SERVICES GERMANY GMBH DE (FREIBURG) participant 0.00
17    Eli Lilly and Company Limited UK (Basingstoke) participant 0.00
18    F. HOFFMANN-LA ROCHE AG CH (BASEL) participant 0.00
19    PFIZER LIMITED UK (SANDWICH) participant 0.00
20    PHARMAMAR, S.A. ES (COLMENAR VIEJO (MADRID)) participant 0.00
21    UNIVERSITAT ZURICH CH (ZURICH) participant 0.00

Map

 Project objective

Cancer remains the leading cause of disease-related death in children. For the ~25% of children who experience relapses of their malignant solid tumors, usually after very intensive first-line therapy, curative treatment options are scarce. Preclinical drug testing to identify promising treatment options that match the molecular make-up of the tumor is hampered by the facts that i) molecular genetic data on pediatric solid tumors from relapsed patients and thus our understanding of tumor evolution and therapy resistance are very limited to date and ii) for many of the high-risk entities no appropriate and molecularly well characterized patient-derived models and/or genetic mouse models are currently available. Thus, quality-assured upfront preclinical testing of novel molecularly targeted compounds in a (saturated) repertoire of well-characterized models will establish the basis to increase therapeutic successes of these drugs in children with solid malignancies. Since these tumors are overall genetically much less complex than their adult counterparts, it is anticipated that it will be easier to identify powerful predictive biomarkers to allow for accurate matching of targets and drugs.

To address this high, as yet unmet clinical need, we have formed the ITCC-P4 consortium consisting of academic and commercial partners from 8 European countries and covering the full spectrum of qualifications needed for quality-assured preclinical drug development including expertise in patient derived models, histopathology, in vivo pharmacology, bioinformatics and data management, centralized testing capabilities, medical expertise regarding the entities in question, regulatory knowledge, and project management of large consortia. With this consortium in a public-private partnership with the participating pharma companies we strongly believe to be ideally positioned to greatly expedite the development of more precise and efficacious drugs for children with malignant solid tumors

 Deliverables

List of deliverables.
International scientific symposium on : “Preclinicalevaluation in pediatric oncology drug development” Websites, patent fillings, videos etc. 2020-04-08 23:48:21

Take a look to the deliverables list in detail:  detailed list of ITCC-P4 deliverables.

 Publications

year authors and title journal last update
List of publications.
2019 Cinzia Zucchini, Maria Cristina Manara, Camilla Cristalli, Marianna Carrabotta, Sara Greco, Rosa Simona Pinca, Cristina Ferrari, Lorena Landuzzi, Michela Pasello, Pier-Luigi Lollini, Marco Gambarotti, Davide Maria Donati, Katia Scotlandi
ROCK2 deprivation leads to the inhibition of tumor growth and metastatic potential in osteosarcoma cells through the modulation of YAP activity
published pages: , ISSN: 1756-9966, DOI: 10.1186/s13046-019-1506-3
Journal of Experimental & Clinical Cancer Research 38/1 2020-04-08
2019 Hannah Kohler, Soeren Latteyer, Georg Sebastian Hönes, Sarah Theurer, Xiao-Hui Liao, Sandra Christoph, Denise Zwanziger, Johannes H. Schulte, Jukka Kero, Hendrik Undeutsch, Samuel Refetoff, Kurt W. Schmid, Dagmar Führer, Lars C. Moeller
Increased Anaplastic Lymphoma Kinase Activity Induces a Poorly Differentiated Thyroid Carcinoma in Mice
published pages: 1438-1446, ISSN: 1050-7256, DOI: 10.1089/thy.2018.0526
Thyroid 29/10 2020-04-08
2019 Lisa Gabler, Daniela Lötsch, Dominik Kirchhofer, Sushilla van Schoonhoven, Hannah M. Schmidt, Lisa Mayr, Christine Pirker, Katharina Neumayer, Carina Dinhof, Lucia Kastler, Amedeo A. Azizi, Christian Dorfer, Thomas Czech, Christine Haberler, Andreas Peyrl, Rajiv Kumar, Irene Slavc, Sabine Spiegl-Kreinecker, Johannes Gojo, Walter Berger
TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAFV600E/TERT promoter double-mutated glioma
published pages: , ISSN: 2051-5960, DOI: 10.1186/s40478-019-0775-6
Acta Neuropathologica Communications 7/1 2020-04-08
2020 Natalie Timme, Youjia Han, Shuai Liu, Hailemichael O. Yosief, Heathcliff Dorado García, Yi Bei, Filippos Klironomos, Ian C. MacArthur, Annabell Szymansky, Jennifer von Stebut, Victor Bardinet, Constantin Dohna, Annette Künkele, Jana Rolff, Patrick Hundsdörfer, Andrej Lissat, Georg Seifert, Angelika Eggert, Johannes H. Schulte, Wei Zhang, Anton G. Henssen
Small-Molecule Dual PLK1 and BRD4 Inhibitors are Active Against Preclinical Models of Pediatric Solid Tumors
published pages: 221-232, ISSN: 1936-5233, DOI: 10.1016/j.tranon.2019.09.013
Translational Oncology 13/2 2020-04-08
2019 Youjia Han, Sven Lindner, Yi Bei, Heathcliff Dorado Garcia, Natalie Timme, Kristina Althoff, Andrea Odersky, Alexander Schramm, Andrej Lissat, Annette Künkele, Hedwig E. Deubzer, Angelika Eggert, Johannes H. Schulte, Anton G. Henssen
Synergistic activity of BET inhibitor MK-8628 and PLK inhibitor Volasertib in preclinical models of medulloblastoma
published pages: 24-33, ISSN: 0304-3835, DOI: 10.1016/j.canlet.2018.12.012
Cancer Letters 445 2020-04-08
2018 Sebastian Brabetz, Sarah E. S. Leary, Susanne N. Gröbner, Madison W. Nakamoto, Huriye Şeker-Cin, Emily J. Girard, Bonnie Cole, Andrew D. Strand, Karina L. Bloom, Volker Hovestadt, Norman L. Mack, Fiona Pakiam, Benjamin Schwalm, Andrey Korshunov, Gnana Prakash Balasubramanian, Paul A. Northcott, Kyle D. Pedro, Joyoti Dey, Stacey Hansen, Sally Ditzler, Peter Lichter, Lukas Chavez, David T. W. Jones, Jan Koster, Stefan M. Pfister, Marcel Kool, James M. Olson
A biobank of patient-derived pediatric brain tumor models
published pages: 1752-1761, ISSN: 1078-8956, DOI: 10.1038/s41591-018-0207-3
Nature Medicine 24/11 2020-04-08
2018 Sebastian Brabetz, Susanne N. Gröbner, Natalie Jäger, Till Milde, Jonas Ecker, Florian Selt, Olaf Witt, Jessica M. Rusert, Jan Koster, Sarah E. Leary, Xiao-Nan Li, Robert J. Wechsler-Reya, James M. Olson, Stefan M. Pfister, and Marcel Kool
A biobank of patient-derived molecularly characterized orthotopic pediatric brain tumor models for preclinical research
published pages: , ISSN: , DOI:
2020-04-08
2018 Sebastian Brabetz
Molecular and preclinical evaluation of patient-derived orthotopic xenograft models of pediatric brain tumors
published pages: , ISSN: , DOI:
2020-04-08

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ITCC-P4" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ITCC-P4" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

PD-MIND (2019)

Parkinson Disease with Mild cognition Impairment treated with Nicotinic agonist Drug

Read More  

RespiriTB (2019)

Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors

Read More  

AB-DiRecT (2019)

Antibiotic Distribution and Recovery in Tissue

Read More